文献速递皮肤肿瘤

黑色素瘤幸存者与高危人群的心理困扰及支持性照护需求:瑞士横断面研究

Psychological distress and unmet supportive care needs in melanoma survivors and patients at high risk of developing melanoma: a Swiss cross-sectional study.
PubMed 文献 · Br J Dermatol · 2026-01-01

该研究在瑞士巴塞尔大学医院皮肤科前瞻性纳入430人(175例黑色素瘤幸存者、255例高危患者),评估心理困扰与黑色素瘤担忧。幸存者对原发或复发黑色素瘤的担忧更突出(26% vs 16%),高危患者总体困扰更高(DT中位数4 vs 2,P<0.001)。ROC分析提示幸存者DT最佳切点为3、高危患者为6。

要点

  • 黑色素瘤幸存者疾病特异性担忧更重(26% vs 16%),高危患者总体困扰更高。
  • 推荐幸存者DT≥3、高危患者DT≥6作为识别需心理肿瘤支持的最佳切点。
  • 所有DT评分段均存在心理支持意愿,提示需灵活、以患者为中心的支持方式。

核心结论

  • 黑色素瘤幸存者疾病特异性担忧更突出,而高危患者总体困扰更高,二者心理肿瘤需求不同。
  • 采用分层DT切点(幸存者≥3、高危患者≥6)可能提高临床相关困扰的检出。
  • 两组人群均存在未满足的心理社会照护需求,皮肤科医生可用于日常筛查。

研究设计与样本

  • 瑞士巴塞尔大学医院皮肤科2021年1月至2024年1月前瞻性收集患者报告结局的横断面研究。
  • 共纳入430人,其中黑色素瘤幸存者175例(41%)、黑色素瘤高危患者255例(59%)。
  • 使用经验证问卷DT、黑色素瘤担忧量表、PHQ及GAD评估主要结局,ROC分析估计DT最佳切点。

主要发现

  • 对原发或后续黑色素瘤的担忧在幸存者中占26%,在高危患者中占16%。
  • 高危患者黑色素瘤担忧低于幸存者,OR 0.56(95%CI 0.34-0.93)。
  • 黑色素瘤担忧预测因素包括离异(OR 3.08,95%CI 1.28-7.38)和较年轻年龄(OR 0.97,95%CI 0.95-0.99)。
  • 高危患者DT中位数4(IQR 2-6),幸存者DT中位数2(IQR 1-5),P<0.001。
  • ROC分析估计幸存者DT最佳切点为3,高危患者为6。

关键数值与推荐

  • 黑色素瘤幸存者DT评分≥3提示可能需要心理肿瘤支持。
  • 黑色素瘤高危患者DT评分≥6提示可能需要心理肿瘤支持。
  • 所有DT评分段均观察到心理支持意愿,支持采用灵活、以患者为中心的方式。

临床怎么用

  • 皮肤科医生可在随访中对幸存者与高危患者分别采用DT≥3和≥6进行心理困扰筛查。
  • 对离异或较年轻患者可加强黑色素瘤担忧评估。
  • 根据DT评分分层提供心理肿瘤转介,并关注所有评分段患者的支持意愿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with melanoma experience worry, anxiety and distress. Screening for psychological distress can facilitate early identification and management. However, little is known about such distress in melanoma survivors and patients at high risk of developing melanoma. OBJECTIVES: The primary outcome was to assess the melanoma-related worry in melanoma survivors and patients at high risk of melanoma. Additionally, a secondary outcome was to determine the optimal Distress Thermometer (DT) cutoff for identifying those needing psycho-oncological support. METHODS: We prospectively collected the distress-related patient-reported outcomes at the Department of Dermatology of the University Hospital in Basel, Switzerland between January 2021 and January 2024. Validated questionnaires including the DT, Melanoma Worry Scale, Patient Health Questionnaire, and Generalized Anxiety Disorder were used to assess the primary outcome. For the secondary outcome, receiver operating characteristic (ROC) analysis was used to estimate the optimal DT cutoff. RESULTS: The study population comprised 430 individuals, including 175 (41%) melanoma survivors and 255 (59%) patients at high risk for melanoma. Worry about getting a primary or subsequent melanoma was more prominent in melanoma survivors (26%) compared with patients at high risk for melanoma (16%). Patients at high risk for melanoma had less melanoma worry compared with melanoma survivors, with an odds ratio (OR) of 0.56 [95% confidence interval (CI) 0.34-0.93]. Melanoma worry predictors included being divorced (OR 3.08, 95% CI 1.28-7.38) and younger age (OR 0.97, 95% CI 0.95-0.99). Patients at high risk of melanoma showed significant higher distress [median DT 4, interquartile range (IQR) 2-6] compared with melanoma survivors (DT 2, IQR 1-5) (P < 0.001). ROC analysis estimated a DT score of 3 as the optimal cutoff for melanoma survivors, whereas a DT score of 6 was optimal in patients at high risk of melanoma. CONCLUSIONS: This study found that melanoma survivors exhibit greater disease-specific worry, whereas patients at high risk for melanoma show increased general distress, underscoring their distinct psycho-oncological needs. Adopting tailored DT cutoffs (≥ 3 for melanoma survivors, ≥ 6 for patients at high risk for melanoma) may improve the detection of clinically relevant distress. Importantly, interest in psychological support was observed across all DT scores, indicating the need for flexible, patient-centred approaches. These findings highlight the unmet need for psychosocial care in both melanoma survivors and patients at high risk of melanoma, and could aid dermatologists in screening patients for psychological distress. Melanoma is one of the most common cancers globally. The number of new cases reached 331 722 in 2022. Melanoma survivors experience fear of recurrence during follow-up visits. They also report high levels of worry, anxiety and other psychological health conditions. However, knowledge about the emotional burden of patients at high risk of developing melanoma is limited. These patients also experience anxiety about developing the disease. Therefore, both of these groups may need psychological and social support. This study investigated the psychological burden of 175 melanoma survivors and 255 patients at high risk of melanoma. The impact of the condition was assessed using validated questionnaires. One of these was the Distress Thermometer (DT) score (a single question rated from 0 to 10). We found that worry about a primary or subsequent melanoma was present in 26% of the melanoma survivors. Overall, 16% of the patients at high risk of melanoma had the same worry. In contrast, levels of general distress were higher in patients at high risk of melanoma. We found that melanoma survivors may need support if their DT score is 3 or higher. Patients at high risk of melanoma may need support if their score is 6 or higher. Our findings suggest that melanoma survivors exhibited high levels of disease-specific worry. On the other hand, patients at high risk of developing melanoma show increased general distress. This highlights distinct psychological needs. Adopting the tailored DT cutoff values of 3 and 6 may improve the detection of clinically relevant distress in these subgroups. These results show an unmet need for psychological care in both melanoma survivors and patients at high risk of melanoma. We hope this study will inform dermatologists in screening during daily practice.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Sieborg J, Zwahlen D, Maul JT, et al. Psychological distress and unmet supportive care needs in melanoma survivors and patients at high risk of developing melanoma: a Swiss cross-sectional study. Br J Dermatol. 2026. PMID: 41205814. doi:10.1093/bjd/ljaf439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。